中国生物制药与清普生物达成QP001独家合作协议
3月6日，中国生物制药（01177）发布公告，本集团与南京清普生物科技有限公司就其研发的国家2类新药QP001在中国大陆地区达成独家合作协议。该产品预计将于近期获得中国国家药品监督管理局批准上市。
QP001是目前唯一一款注册分类为国家2类新药的美洛昔康注射液，具有长效、强效的特点，针对术后疼痛进行治疗。研究显示，QP001在药效末期（18-24小时）仍可保持显著镇痛效果，相较于传统非选择性NSAIDs，QP001作为选择性环氧合酶-2抑制剂，对COX-1影响较小，安全性优。临床研究表明，QP001在骨科手术和腹部手术受试者中显著降低吗啡使用量，分别降低56.3%和46%。
目前，国内尚无用于治疗术后疼痛的美洛昔康注射液，术后疼痛的发生率高达91.8%。中国住院患者手术超过8200万次，但术后镇痛的普及率偏低。QP001凭借其安全、强效、长效的特性，有望满足术后镇痛领域的临床需求，成为本集团镇痛领域的下一款重磅产品。
（文章来源：财中社）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10